Reference

The combination of nisoxetine, a norepinephrine reuptake inhibitor, and a dopamine reuptake inhibitor appears to produce a combined effect that significantly reduces food intake, which may not be as strong when each is used individually. According to a study published in Neuropsychopharmacology, the acute combined inhibition of dopamine (DA) and norepinephrine (NE) reuptake results in an additive reduction in food intake, especially in lean and obese mice on a high-fat diet. This suggests that both norepinephrine and dopamine pathways are involved in regulating feeding behavior, and when both are targeted simultaneously, their effects on reducing food intake are enhanced source.

The underlying mechanism can be attributed to the influence of these neurotransmitters on the brain's reward and appetite pathways. Norepinephrine and dopamine play crucial roles in regulating mood, motivation, and feeding behaviors. By inhibiting the reuptake of both, the combination may effectively suppress the desire to eat by enhancing satiety signaling or altering the reward value of food, thus leading to a significant reduction in food intake.

This information highlights the potential therapeutic benefits of using combination therapies in managing eating disorders or obesity, where altering the activities of multiple neurotransmitter systems can be more effective than targeting them individually.